US 12,173,037 B1
Mutant NGAL proteins and uses thereof
Jonathan Barasch, New York, NY (US); and Andong Qiu, Bronx, NY (US)
Assigned to The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed on Nov. 9, 2020, as Appl. No. 17/093,055.
Application 17/093,055 is a division of application No. 15/453,109, filed on Mar. 8, 2017, granted, now 10,829,525, issued on Nov. 10, 2020.
Application 15/453,109 is a division of application No. 14/719,204, filed on May 21, 2015, granted, now 9,624,281, issued on Apr. 18, 2017.
Application 14/719,204 is a continuation in part of application No. PCT/US2013/071344, filed on Nov. 21, 2013.
Claims priority of provisional application 61/729,323, filed on Nov. 21, 2012.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/47 (2013.01) [A61K 38/00 (2013.01)] 9 Claims
 
1. A method of treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 253, wherein said polypeptide is able to bind to a siderophore and is excreted in the urine of the subject after systemic administration of said pharmaceutical composition to the subject.